Justices Won't Review Class Cert. In Diabetes Drug Risk Case

By Mark Payne · March 24, 2026, 1:23 PM EDT

The U.S. Supreme Court has declined to review whether a federal court can certify a class of third-party payors who claim drugmakers hid the cancer risks of an anti-diabetes drug....

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order List

Case Information

Case Title

Takeda Pharmaceutical Company Limited, a Japanese Corporation, et al., Petitioners v. Painters and Allied Trades District Council 82 Health Care Fund, et al.

Case Number

Court

Supreme Court

Nature of Suit

4470 Civil (Rico)

Date Filed

December 02, 2025

Recent Articles By Mark

March 23, 2026
Feds Approve Minnesota's Plan To Combat Medicaid Fraud
March 23, 2026
Justices Won't Review Lab Owner's Kickback Conviction
March 13, 2026
Sandoz Appealing Ruling Over Amgen's Enbrel Biosimilar
March 13, 2026
Texas Justices Clear Way For State's Trans Care Probe
March 12, 2026
Doc's Hands Aren't Property, Texas Panel Rules In Death Suit
March 11, 2026
VA, DOJ Cut Deal To Make Attys Mental Health Guardians
March 10, 2026
2nd Circ. Revives Geico's Suit Over Acupuncture Referrals
March 10, 2026
Abortion Ban, Drug Pricing: Health Litigation Week In Review
March 09, 2026
Abortion Rights Group, SD Agree to End Gas Station Ads Row
March 06, 2026
FDA Vaccine Chief Prasad To Exit Agency For 2nd Time